Buccal Misoprostol During Cesarean Section for Preventing Postpartum Hemorrhage

Summary

Objective: to demonstrate that buccal misoprostol administration during cesarean delivery in women with risk factors for uterine atony decreases the need for additional uterotonic medications, uterine atony and postpartum hemorrhage. Design: randomized, double-blinded, placebo-controlled trial.

Timeline

Start

2008-02

Primary completion

2013-12

Completion

2013-12

Outcome

Met primary endpoint

registry Misoprostol vs Folic Acid; p <0.01; Fisher Exact NCT01733329 ↗

paper 24 (40%) women in the placebo group versus 6 (10%) women in the misoprostol group PMID 26534874 ↗

Publications

• Background Hamm J, Russell Z, Botha T, Carlan SJ, Richichi K. Buccal misoprostol to prevent hemorrhage at cesarean delivery: a randomized study. Am J Obstet Gynecol. 2005 May;192(5):1404-6. doi: 10.1016/j.ajog.2004.12.033.
• Hernandez-Castro F, Lopez-Serna N, Trevino-Salinas EM, Soria-Lopez JA, Sordia-Hernandez LH, Cardenas-Estrada E. Randomized double-blind placebo-controlled trial of buccal misoprostol to reduce the need for additional uterotonic drugs during cesarean delivery. Int J Gynaecol Obstet. 2016 Feb;132(2):184-7. doi: 10.1016/j.ijgo.2015.06.060. Epub 2015 Oct 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Misoprostol	Other / unclassified	400 ug	Other

Indications

No indication recorded.